Stock analysts at Leede Financial issued their FY2027 earnings per share (EPS) estimates for Cipher Pharmaceuticals in a ...

Cipher Pharmaceuticals (TSE:CPH) has had a rough three months with its share price down 21%. However, stock prices ...

Following the company’s fourth quarter results, Leede Financial analyst Douglas Loe has upgraded Cipher Pharmaceuticals.

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Cipher Pharmaceuticals quarterly conference call for the company's Full Year and Q4 2024 results. [Operator Instructions].

Research analysts at Leede Financial lowered their FY2025 earnings per share estimates for Cipher Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. Leede Financial ...

Cipher Pharmaceuticals Inc. (CPH) reported its fourth-quarter 2024 earnings, revealing a significant increase in revenue and a notable surge in stock price. Despite missing earnings per share (EPS ...

Cipher Pharmaceuticals Inc. (CPH) reported its fourth-quarter 2024 earnings, revealing a significant increase in revenue and a notable surge in stock price. Despite missing earnings per share (EPS) ...

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology.